Regen BioPharma Inc (RGBP)

[ronrooster]

Not new, however just came accross this info re dCellVax.

BENITEC BIOPHARMA LIMITED
Directors' Report
for the half-year ended December 31, 2019
Review of Operations continued
Licensed programs continued
Cancer Immunotherapy: In August 2013, an exclusive, royalty-bearing, worldwide license was granted to a U.S.-based biotechnology company, Regen Biopharma Inc. to use ddRNAi for silencing expression of indoleamine 2,3—

dioxygenase, or IDO, in dendritic cells. Regen is developing a cancer immunotherapy using the licensed technology. IDO is associated with immune-suppression and is overexpressed in some cancers. Regen has reported preclinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO may significantly enhance their efficacy in cancer immunotherapy. Regen's first treatment, which is for breast cancer, is called dCellVax.
Regen advised Benitec in July 2019 that they intend to terminate the agreement.